相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Agonist antibody discovery: Experimental, computational, and rational engineering approaches
John S. Schardt et al.
DRUG DISCOVERY TODAY (2022)
An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
Sarah Chan et al.
NATURE CANCER (2022)
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
Beatrice T. Wang et al.
MOLECULAR CANCER THERAPEUTICS (2021)
An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Marta Compte et al.
CLINICAL CANCER RESEARCH (2021)
FDA approves 100th monoclonal antibody product
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2021)
Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma
Hilma J. van der Horst et al.
BLOOD ADVANCES (2021)
Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models
Karsten M. Warwas et al.
FRONTIERS IN IMMUNOLOGY (2021)
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Martin Gutierrez et al.
CLINICAL CANCER RESEARCH (2021)
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
Ajay K. Gopal et al.
CLINICAL CANCER RESEARCH (2020)
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity
Xiaojie Yu et al.
CANCER CELL (2020)
CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement
Miguel Gaspar et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation
Fabian Junker et al.
FRONTIERS IN IMMUNOLOGY (2020)
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
Shuyu Huang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism
Marije B. Overdijk et al.
MOLECULAR CANCER THERAPEUTICS (2020)
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells
Lucia Campos Carrascosa et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Domain binding and isotype dictate the activity of anti-human OX40 antibodies
Jordana Griffiths et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
Xinyue Qi et al.
NATURE COMMUNICATIONS (2019)
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Anne Mansson Kvarnhammar et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members
Yanli Yang et al.
MABS (2019)
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
Christina Claus et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity
Pamela Zhang et al.
CELL REPORTS (2019)
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Rui Wang et al.
CLINICAL CANCER RESEARCH (2019)
Identification of New DR5 Agonistic Nanobodies and Generation of Multivalent Nanobody Constructs for Cancer Treatment
Golnaz Sadeghnezhad et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility
Xiaobo Liu et al.
NATURE COMMUNICATIONS (2019)
MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer
Yoshimi Endo Greer et al.
BREAST CANCER RESEARCH (2019)
Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility
Lilia A. Rabia et al.
BIOCHEMICAL ENGINEERING JOURNAL (2018)
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies
Xiaojie Yu et al.
CANCER CELL (2018)
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2018)
The promise and challenges of immune agonist antibody development in cancer
Patrick A. Mayes et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity
Jun Ishihara et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
Sarah L. Buchan et al.
IMMUNITY (2018)
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
S. Michael Chin et al.
NATURE COMMUNICATIONS (2018)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2017)
Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization
Di Zhang et al.
MABS (2017)
MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential
Natalie J. Tigue et al.
ONCOIMMUNOLOGY (2017)
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2017)
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
Rony Dahan et al.
CANCER CELL (2016)
Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
Di Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
Peter Brunker et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Regulation of tumour necrosis factor signalling: live or let die
Dirk Brenner et al.
NATURE REVIEWS IMMUNOLOGY (2015)
TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future
Lisa M. Sedger et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Yannick Bulliard et al.
IMMUNOLOGY AND CELL BIOLOGY (2014)
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Andrew J. S. Furness et al.
TRENDS IN IMMUNOLOGY (2014)
Engineered antibody Fc variant with selectively enhanced FcRIIb binding over both FcRIIaR131 and FcRIIaH131
F. Mimoto et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H. Vonderheide et al.
ONCOIMMUNOLOGY (2013)
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement
Fubin Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Toward experimental assessment of receptor occupancy: TGN1412 revisited
Zoe Waibler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Structural and functional characterization of disulfide isoforms of the human IgG2 subclass
Thomas M. Dillon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Cytokine Storm in the phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics
Richard Stebbings et al.
JOURNAL OF IMMUNOLOGY (2007)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
分享论文
